Expand all sections

Benralizumab

Fasenra

Extended indication

Extension of indication to include treatment of eosinophilic granulomatosis.
Therapeutic value

No estimate possible yet
Registration phase

Registration application pending

Product

Active substance

Benralizumab
Domain

Lung diseases
Reason of inclusion

Indication extension
Main indication

Lung diseases other
Extended indication

Extension of indication to include treatment of eosinophilic granulomatosis.
Proprietary name

Fasenra
Manufacturer

AstraZeneca
Portfolio holder

AstraZeneca
Mechanism of action

Interleukin inhibitor
Route of administration

Subcutaneous
Therapeutical formulation

Injection
Budgetting framework

Intermural (MSZ)

Registration

Registration route

Centralised (EMA)
Type of trajectory

Normal trajectory
ATMP

No
Submission date

December 2023
Expected Registration

October 2024
Orphan drug

No
Registration phase

Registration application pending

Therapeutic value

Therapeutic value

No estimate possible yet
References 
NCT04157348

Expected patient volume per year

There is currently nothing known about the expected patient volume.

Expected cost per patient per year

There is currently nothing known about the expected cost.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

There is currently nothing known about indication extensions.

Other information

There is currently no futher information available.